<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30852530</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>09</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Protocol for a systematic review and meta-analysis of fractional dose compared with standard dose inactivated polio vaccination in children.</ArticleTitle><Pagination><StartPage>e023308</StartPage><MedlinePgn>e023308</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e023308</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2018-023308</ELocationID><Abstract><AbstractText Label="INTRODUCTION">WHO recommends the introduction of at least one single dose of inactivated polio vaccine (IPV) in routine immunisation schedules. Thus, there has been an increased demand and concurrent supply shortages of IPV worldwide. One of the strategies to improve access is the use of fractional instead of full doses of IPV. We aim to compare the effects of fractional with standard doses of IPV.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">We will include randomised trials, non-randomised trials, case-control studies and cohort studies that compared fractional with full doses of IPV among children aged 5&#x2009;years or younger. We will search for eligible studies among published and grey literature. Two authors will independently screen the results of the search, select studies, extract data and assess risk of bias. We will stratify analyses by study design, type of poliovirus, type of outcome measure and number of IPV doses given. For each type of poliovirus, we will pool the outcome data from studies using random-effects meta-analyses. Statistical heterogeneity will be assessed using the &#x3c7;<sup>2</sup> test of homogeneity and quantified using the I<sup>2</sup> statistic. To investigate statistical heterogeneity, subgroup analyses will be performed based on the timing of the first fractional dose, age of administration, immunisation schedules and country income status. Sensitivity analyses will be used to assess if the effect of IPV fractional dosing is affected by study design, risk of bias and methods of meta-analysis.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">We obtained approval from the University of Cape Town Human Research Ethics Committee (HREC REF: 412/2018). The findings of this review will provide evidence for decision-making with regards to IPV dosage, eventually improving access to the vaccine by stretching vaccine supplies. The results will be published in the University of Cape Town online library and in a peer reviewed journal.</AbstractText><AbstractText Label="PROSPERO REGISTRATION NUMBER">CRD42018092647.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mashunye</LastName><ForeName>Thandiwe Runyararo</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ndwandwe</LastName><ForeName>Duduzile Edith</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Cochrane South Africa, South African Medical Research Council, Tygerberg, Western Cape, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dube</LastName><ForeName>Kopano Rebaona</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Cochrane South Africa, South African Medical Research Council, Tygerberg, Western Cape, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shey</LastName><ForeName>Muki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Cape Town, Faculty of Medicine, Cape Town, Western Cape, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Sciences Library, University of Cape Town, Cape Town, Western Cape, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiysonge</LastName><ForeName>Charles Shey</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0002-1273-4779</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cochrane South Africa, South African Medical Research Council, Tygerberg, Western Cape, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Epidemiology and Biostatistics,Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, Western Cape, South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="Y">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007271" MajorTopicYN="N">Injections, Intradermal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="N">Systematic Reviews as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dose-sparing</Keyword><Keyword MajorTopicYN="N">fractional dosing</Keyword><Keyword MajorTopicYN="N">inactivated polio vaccine</Keyword><Keyword MajorTopicYN="N">ipv</Keyword><Keyword MajorTopicYN="N">polio eradication</Keyword><Keyword MajorTopicYN="N">vaccine shortage</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30852530</ArticleId><ArticleId IdType="pmc">PMC6429719</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2018-023308</ArticleId><ArticleId IdType="pii">bmjopen-2018-023308</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Wiysonge CS.
Africa is within reach of being declared a polio free region. The Conversation
2015. 
https://theconversation.com/africa-is-within-reach-of-being-declared-a-polio-free-region-44786 (Accessed 18 Mar 2018).</Citation></Reference><Reference><Citation>Kliegman R, Behrman RE, Nelson WE. Nelson textbook of pediatrics. 20 ed Phialdelphia, PA: Elsevier, 2016.</Citation></Reference><Reference><Citation>
World Health Organisation. Polio vaccines: WHO position paper - March, 2016 in the Weekly epidemiological record: 25 March 2016. 2016;91, 12:145&#x2013;68
http://www.who.int/wer/2016/wer9112.pdf?ua=1.</Citation></Reference><Reference><Citation>Okayasu H, Sutter RW, Jafari HS, et al. . Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis 2014;210(Suppl 1):S459&#x2013;64. 10.1093/infdis/jiu128</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu128</ArticleId><ArticleId IdType="pubmed">25316868</ArticleId></ArticleIdList></Reference><Reference><Citation>
UNICEF Supply Division. OPV Supply &amp; Outlook. 2013. 
https://www.unicef.org/supply/files/Oral_polio_vaccine_update.pdfCurrent
</Citation></Reference><Reference><Citation>Burns CC, Diop OM, Sutter RW, et al. . Vaccine-derived polioviruses. J Infect Dis 2014;210:S283&#x2013;93. 10.1093/infdis/jiu295</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu295</ArticleId><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt LR, Est&#xed;variz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014;210(Suppl 1):S380&#x2013;9. 10.1093/infdis/jiu184</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu184</ArticleId><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>
Global Polio Eradication Initiative. Polio Eradication &amp; Endgame Strategy 2013-2018. 2013. 
http://polioeradication.org/wpcontent/uploads/2016/07/PEESP_EN_A4.pdf.</Citation></Reference><Reference><Citation>
Zipursky S on behalf of the IMG Polio Partners&#x2019; Group. Presentation on the Update on the switch and IPV supply, Geneva. 2016. 
http://polioeradication.org/wp-content/uploads/2016/07/PPG_Mtg20160624_Presentation2.pdf (Accessed on 11 Jan 2018).</Citation></Reference><Reference><Citation>
Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 &#x2013; conclusions and recommendations in the Weekly epidemiological record. 2013;88:1&#x2013;16
http://www.who.int/wer/2013/wer8801.pdf.</Citation><ArticleIdList><ArticleId IdType="pubmed">23311010</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Molodecky NA, Pallansch MA, et al. . Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule. Vaccine 2017;35:2993&#x2013;8. 10.1016/j.vaccine.2017.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.03.008</ArticleId><ArticleId IdType="pmc">PMC10423713</ArticleId><ArticleId IdType="pubmed">28434691</ArticleId></ArticleIdList></Reference><Reference><Citation>UNICEF Supply Division: Inactivated Polio Vaccine Supply and Demand Update, 2016. 
https://www.unicef.org/supply/files/Inactivated_Polio_Vaccine_(IPV)_-_september_2016.pdf (Accessed 11 Jan 2018).</Citation></Reference><Reference><Citation>
GAVI and GPEI IPV Supply and Procurement Roadmap In support of the Polio Eradication Endgame Strategy Update August 2017: 4 The Market Shaping Goal. http://www.gavi.org/library/gavi./supply-procurement/ipv-roadmap-public-summary/ (accessed on 11 Jan 2018).</Citation></Reference><Reference><Citation>
UNICEF. Data showing awarded price per dose (in US$ or EUR) per product per supplier per calendar year, based on supply agreements. https://www.unicef.org/supply/files/IPV.pdf (Accessed on 11 Jan 2018).</Citation></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. . Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016. MMWR Morb Mortal Wkly Rep 2016;65:934&#x2013;8. 10.15585/mmwr.mm6535a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6535a3</ArticleId><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis I, Ottosen A, Rubin J, et al. . A supply and demand management perspective on the accelerated global introductions of inactivated poliovirus vaccine in a constrained supply market. J Infect Dis 2017;216(suppl_1):S33&#x2013;9. 10.1093/infdis/jiw550</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw550</ArticleId><ArticleId IdType="pmc">PMC5853471</ArticleId><ArticleId IdType="pubmed">28838159</ArticleId></ArticleIdList></Reference><Reference><Citation>
Global Polio Eradication Initiative. Use of fractional dose IPV in routine immunization programmes: Considerations for decision-making. 2017. 
http://www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/inactivated_polio_vaccine/fIPV_considerations_for_decision-making_April2017.pdf (Accessed 11 Jan 2018).</Citation></Reference><Reference><Citation>
UNICEF. Update on IPV introduction and use of fractional dose given intradermal with 0.1 ml syringe. 2017. 
https://www.unicef.org/supply/files/6a._Fractional_IPV_and_syringes.pdf (Accessed 11 Jan 2018).</Citation></Reference><Reference><Citation>
Global Polio Eradication Initiative. Post-Certification Strategic Plan (Review draft). 2017. 
http://www.who.int/immunization/sage/meetings/2017/october/4_polio_Post_Certification_Strategic_Plan_Draft_Web.pdf (accessed 23 Nov 2017).</Citation></Reference><Reference><Citation>Resik S, Tejeda A, Lago PM, Mas Lago P, et al. . Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010;201:1344&#x2013;52. 10.1086/651611</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/651611</ArticleId><ArticleId IdType="pubmed">20350164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed AJ, AlAwaidy S, Bawikar S, et al. . Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010;362:2351&#x2013;9. 10.1056/NEJMoa0909383</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0909383</ArticleId><ArticleId IdType="pubmed">20573923</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Tejeda A, Sutter RW, et al. . Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013;368:416&#x2013;24. 10.1056/NEJMoa1202541</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202541</ArticleId><ArticleId IdType="pubmed">23363495</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Zaman K, Est&#xed;variz CF, et al. . Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine 2015;33:6816&#x2013;22. 10.1016/j.vaccine.2015.09.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.09.039</ArticleId><ArticleId IdType="pmc">PMC10423714</ArticleId><ArticleId IdType="pubmed">26476367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008;26:3197&#x2013;208. 10.1016/j.vaccine.2008.03.095</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.03.095</ArticleId><ArticleId IdType="pubmed">18486285</ArticleId></ArticleIdList></Reference><Reference><Citation>Okayasu H, Sein C, Chang Blanc D, et al. . Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization. J Infect Dis 2017;216(suppl_1):S161&#x2013;S167. 10.1093/infdis/jix038</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix038</ArticleId><ArticleId IdType="pmc">PMC5853966</ArticleId><ArticleId IdType="pubmed">28838185</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl S, Verma H, Bhatnagar P, et al. . Fractional-dose inactivated poliovirus vaccine immunization campaign - telangana state, India, June 2016. MMWR Morb Mortal Wkly Rep 2016;65:859&#x2013;63. 10.15585/mmwr.mm6533a5</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6533a5</ArticleId><ArticleId IdType="pubmed">27559683</ArticleId></ArticleIdList></Reference><Reference><Citation>
United Nations. The 2030 agenda for sustainable development. 2015. 
https://sustainabledevelopment.un.org/content/documents/21252030%20Agenda%20for%20Sustainable%20Development%20web.pdf (Accessed 13 Jan 2018).</Citation></Reference><Reference><Citation>Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis 2014;210 Suppl 1:S439&#x2013;S446. 10.1093/infdis/jit601</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit601</ArticleId><ArticleId IdType="pmc">PMC4197908</ArticleId><ArticleId IdType="pubmed">24634499</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiysonge CS, Kamadjeu R, Tsague L. Systematic reviews in context: highlighting systematic reviews relevant to Africa in the Pan African Medical Journal. Pan Afr Med J 2016;24:180 10.11604/pamj.2016.24.180.10100</Citation><ArticleIdList><ArticleId IdType="doi">10.11604/pamj.2016.24.180.10100</ArticleId><ArticleId IdType="pmc">PMC5072844</ArticleId><ArticleId IdType="pubmed">27795777</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Oxman AD, Vist GE, et al. . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924&#x2013;6. 10.1136/bmj.39489.470347.AD</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39489.470347.AD</ArticleId><ArticleId IdType="pmc">PMC2335261</ArticleId><ArticleId IdType="pubmed">18436948</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Carr W. ACIP Evidence-Based Recommendations Work Group ACIP Evidence Based Recommendations Work Group. Updated Framework for Development of Evidence-Based Recommendations by the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2018;67:1271&#x2013;2. 10.15585/mmwr.mm6745a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6745a4</ArticleId><ArticleId IdType="pmc">PMC6290811</ArticleId><ArticleId IdType="pubmed">30439877</ArticleId></ArticleIdList></Reference><Reference><Citation>
Higgins JPT, Green S. 
Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]: The Cochrane Collaboration. 2011. 
http://handbook.cochrane.org (Accessed 20 Nov 2017).</Citation></Reference><Reference><Citation>Sterne JA, Hern&#xe1;n MA, Reeves BC, et al. . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919 10.1136/bmj.i4919</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, et al. . Measuring inconsistency in meta-analyses. BMJ 2003;327:557&#x2013;60. 10.1136/bmj.327.7414.557</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>
The World Bank Group. Data. Countries an Economies. https://data.worldbank.org/country/ (Accessed 2 Feb 2018).</Citation></Reference><Reference><Citation>Sterne JA, Sutton AJ, Ioannidis JP, et al. . Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002 10.1136/bmj.d4002</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d4002</ArticleId><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch V, Petticrew M, Tugwell P, et al. . PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. PLoS Med 2012;9:e1001333 10.1371/journal.pmed.1001333</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001333</ArticleId><ArticleId IdType="pmc">PMC3484052</ArticleId><ArticleId IdType="pubmed">23222917</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Shamseer L, Clarke M, et al. . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1):1 10.1186/2046-4053-4-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2046-4053-4-1</ArticleId><ArticleId IdType="pmc">PMC4320440</ArticleId><ArticleId IdType="pubmed">25554246</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamseer L, Moher D, Clarke M, et al. . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647 10.1136/bmj.g7647</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g7647</ArticleId><ArticleId IdType="pubmed">25555855</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt G, Oxman AD, Akl EA, et al. . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383&#x2013;94. 10.1016/j.jclinepi.2010.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.04.026</ArticleId><ArticleId IdType="pubmed">21195583</ArticleId></ArticleIdList></Reference><Reference><Citation>Balshem H, Helfand M, Sch&#xfc;nemann HJ, et al. . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401&#x2013;6. 10.1016/j.jclinepi.2010.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.07.015</ArticleId><ArticleId IdType="pubmed">21208779</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>